205 related articles for article (PubMed ID: 23322141)
1. Evolving therapeutic options for type 2 diabetes mellitus: an overview.
Guthrie RM
Postgrad Med; 2012 Nov; 124(6):82-9. PubMed ID: 23322141
[TBL] [Abstract][Full Text] [Related]
2. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
[TBL] [Abstract][Full Text] [Related]
3. The backbone of oral glucose-lowering therapy: time for a paradigm shift?
Seufert J
Fundam Clin Pharmacol; 2009 Dec; 23(6):651-67. PubMed ID: 19469803
[TBL] [Abstract][Full Text] [Related]
4. What to add in with metformin in type 2 diabetes?
Petrie JR; Adler A; Vella S
QJM; 2011 Mar; 104(3):185-92. PubMed ID: 21156663
[TBL] [Abstract][Full Text] [Related]
5. Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment.
Harrigan RA; Nathan MS; Beattie P
Ann Emerg Med; 2001 Jul; 38(1):68-78. PubMed ID: 11423816
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.
Tahrani AA; Barnett AH; Bailey CJ
Nat Rev Endocrinol; 2016 Oct; 12(10):566-92. PubMed ID: 27339889
[TBL] [Abstract][Full Text] [Related]
7. Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes.
Chaudhuri A; Dandona P
Diabetes Obes Metab; 2011 Oct; 13(10):869-79. PubMed ID: 21569185
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?
Paolisso G; Monami M; Marfella R; Rizzo MR; Mannucci E
Adv Ther; 2012 Mar; 29(3):218-33. PubMed ID: 22411425
[TBL] [Abstract][Full Text] [Related]
9. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ
Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
[TBL] [Abstract][Full Text] [Related]
10. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Halimi S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
[TBL] [Abstract][Full Text] [Related]
11. Which oral agent to use when metformin is no longer effective?
Bannon M
QJM; 2011 Mar; 104(3):183-4. PubMed ID: 21330402
[No Abstract] [Full Text] [Related]
12. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
Home P
Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S33-42. PubMed ID: 22650223
[TBL] [Abstract][Full Text] [Related]
14. Use of noninsulin antidiabetic medications in hospitalized patients.
Kopecky C
Crit Care Nurs Clin North Am; 2013 Mar; 25(1):39-53. PubMed ID: 23410645
[TBL] [Abstract][Full Text] [Related]
15. Diabetes under control: Understanding oral antidiabetic agents.
Longo R
Am J Nurs; 2010 Feb; 110(2):49-52. PubMed ID: 20107402
[No Abstract] [Full Text] [Related]
16. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Gallwitz B
Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
[TBL] [Abstract][Full Text] [Related]
17. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
[No Abstract] [Full Text] [Related]
18. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
Penfornis A; Borot S; Raccah D
Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):839-57. PubMed ID: 24669954
[TBL] [Abstract][Full Text] [Related]
20. Oral combination therapy in primary care.
Kalra S; Gupta Y
J Pak Med Assoc; 2015 May; 65(5):574-5. PubMed ID: 26028398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
